Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole Refractory Esophageal Candidiasis. A Case Report from the Furi Study

Favourable Clinical Outcome of Two Patients with Candida spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases

Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Efficacy of Ibrexafungerp (IBX, formerly SCY-078) in the Treatment of Candida auris Cutaneous Infection in a Guinea Pig Model

Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI study

Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against Candida auris: In Vitro, In Vivo and Clinical Case Studies of Candidemia

Candida auris is Highly In Vitro Susceptible to Ibrexafungerp (formerly SCY-078) in EUCAST Antifungal Susceptibility Testing